

NEW DATA SHOW USE OF ABBOTT'S FREESTYLE® LIBRE SYSTEM REDUCES ALL-CAUSE, DIABETIC KETOACIDOSIS-RELATED HOSPITALIZATION RATES AND ACUTE DIABETES EVENTS

- Findings from the RELIEF study in France showed for the first time, in the largest retrospective analysis of its kind of nearly 75,000 people living with diabetes, use of the FreeStyle Libre system dramatically decreases diabetic ketoacidosis-related hospitalizations

- Additional real-world data demonstrate meaningful outcomes for people living with diabetes who use Abbott's glucose sensing technology, including lower rates of acute diabetes events and all-cause hospitalizations as well as significant reductions in HbA1c levels

ABBOTT PARK, Ill., June 16, 2020 /[PRNewswire](#)/ -- Today, Abbott (NYSE: ABT) announced results from multiple new real-world studies^{1,2,3,4} that demonstrate how use of the FreeStyle Libre system, the world-leading⁵ continuous glucose monitoring (CGM) technology, can lead to significant clinical benefits among people living with type 1 and type 2 diabetes. Notable findings, presented at this year's American Diabetes Association (ADA) 80th Scientific Sessions, show that using the FreeStyle Libre technology is associated with substantial reductions in hospitalizations from diabetic ketoacidosis (DKA), a serious condition that can lead to diabetic coma or even death.⁶ Results also showed a decrease in rates of acute diabetes events (ADE) and all-cause hospitalizations as well as lowered and sustained hemoglobin A1c (HbA1C) levels.

Data were presented as part of the RELIEF study (Abstract 68-OR),¹ the largest retrospective study of its kind analyzing the impact of FreeStyle Libre portfolio use on the incidence of hospitalizations for DKA. In the study, researchers assessed nationwide reimbursement claims data in France of 74,158 people living with diabetes, including 33,203 people with type 1 diabetes and 40,955 people with type 2 diabetes.

Notable findings demonstrated:

- Overall, annual DKA rates dramatically dropped by 52% in those with type 1 diabetes and 47% in those with type 2 diabetes when using the FreeStyle Libre system.
- Greatest reductions in DKA-related hospitalizations occurred in people who did not conduct traditional fingerstick testing, as well as those who performed fingersticks more than five times per day, regardless of previous test strip usage.
 - In those who did not fingerstick, results showed decreases of 60% and 51% in people with type 1 and type 2 diabetes, respectively.
 - For people who performed fingersticks more than five times per day, findings showed drops of 59% for people with type 1 diabetes and 52% for people with type 2 diabetes.

"The results of this study strongly support our hypothesis that the use of the FreeStyle Libre technology enables people to identify and reduce hyperglycemia, and in turn, limit diabetic ketoacidosis," said Ronan Roussel, M.D., Ph.D., chief of the endocrinology, diabetes and nutrition department at Hôpital Bichat, Fédération de Diabétologie, AP-HP in Paris, France, and lead author for the RELIEF study. "These data are suggestive of significant, long-term health benefits and cost savings from use of Abbott's sensor-based glucose monitoring system."

ADDITIONAL STUDIES DEMONSTRATE MEANINGFUL OUTCOMES FOR PEOPLE WITH DIABETES

Additional abstracts presented at ADA showed:

- **Sustainable HbA1c Decrease at 12 Months for Adults with Type 1 and Type 2 Diabetes Using the FreeStyle Libre System²** (Abstract 74-LB): Through a real-world analysis of the National Diabetes Register in Sweden, researchers identified 39,554 people with type 1 or type 2 diabetes using the FreeStyle Libre system. A subgroup of people who had used the FreeStyle Libre system for nine to 15 months were able to significantly lower their HbA1C levels with a sustained effect at 12 months (0.44% drop in people with type 1 diabetes and a 0.66% reduction in those with type 2 diabetes). These A1c changes are usually associated with intensification of diabetes treatment regimens and highlight the important clinical benefits the FreeStyle Libre system may have in people with diabetes.
- **FreeStyle Libre System Use is Associated with Reduction in Inpatient and Outpatient Emergency Acute Diabetes Events (ADE) and All-Cause Hospitalizations in Patients with Type 2 Diabetes³** (69-OR): In a retrospective, observational analysis of 1,244 people with type 2 diabetes on short-acting insulin in the U.S., researchers found use of the FreeStyle Libre system was associated with substantial reductions of 51% in acute diabetes events (ADE) and 28% in all-cause hospitalizations. These findings suggest positive health economics outcomes and use of the FreeStyle Libre technology, priced at a third of the cost of other CGMs,⁷ provides significant cost-savings.
- **Utilization of Continuous Glucose Monitors is Associated with Reduction in Inpatient and Outpatient Emergency Acute Diabetes Events (ADE) Regardless of Prior Blood Test Strip Usage⁴** (875-P): Through a retrospective, observational study of 12,521 people living with type 1 or type 2 diabetes in the U.S., researchers found that use of CGMs, including Abbott's FreeStyle Libre system, was associated with a 46% reduction in ADE, regardless of test strip usage prior to the start of using CGMs.

"These new data further reinforce the life-changing benefits of Abbott's glucose sensing technology in delivering meaningful outcomes for people living with both type 1 and type 2 diabetes," said Mahmood Kazemi, M.D., divisional vice president, global medical and scientific affairs and chief medical officer, Diabetes Care, Abbott. "Through improved glucose control and reductions in diabetes-related complications or hospitalizations, the findings underpin why millions of people globally choose our FreeStyle Libre system to manage their condition and improve their quality of life."

About the FreeStyle Libre System:

Abbott's FreeStyle Libre technology, the #1 sensor-based glucose monitoring system used worldwide,⁵ reads glucose levels through a sensor that can be worn on the back of the upper arm, eliminating the need for fingersticks.⁸ The FreeStyle Libre portfolio has changed the lives of more than two million people across 50 countries⁹ and has secured partial or full reimbursement in 36 countries, including France, Ireland, Japan, the United Kingdom, and the U.S.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

FreeStyle Libre and FreeStyle Libre 14 day Flash Glucose Monitoring systems are continuous glucose monitoring (CGM) devices indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. The systems are intended for single patient use and require a prescription.

CONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.

WARNINGS/LIMITATIONS: Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The system does not have alarms unless the sensor is scanned, and the system contains small parts that may be dangerous if swallowed. The system is not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. When using FreeStyle LibreLink app, access to a blood glucose monitoring system is required as the app does not provide one. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit www.freestylelibre.us for detailed indications for use and safety information.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

¹ Roussel et al. Dramatic drop in ketoacidosis rate after FreeStyle Libre system initiation in type 1 and type 2 diabetes in France, especially in people with low self-monitoring of blood glucose (SMBG): a nationwide study.

² Eeg-Olofsson et al. Sustainable HbA1c decrease at 12 months for adults with Type 1 and Type 2 Diabetes using the FreeStyle Libre System: a study within the National Diabetes Register in Sweden.

³ Bergenstal et al. FreeStyle Libre® System Use Is Associated with Reduction in Inpatient and Outpatient Emergency Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes.

⁴ Hirsch et al. Utilization of Continuous Glucose Monitors is Associated with Reduction in Inpatient and Outpatient Emergency Acute Diabetes Events Regardless of Prior Blood Test Strip Usage.

⁵ Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.

⁶ DKA (Ketoacidosis) and Ketones. American Diabetes Association.

<https://www.diabetes.org/diabetes/complications/dka-ketoacidosis-ketones>.

⁷ Based on a comparison of list prices of the FreeStyle Libre portfolio versus competitor CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

⁸ Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

⁹ Data on file, Abbott Diabetes Care.

SOURCE Abbott

For further information: Abbott Media: Molly Cornbleet, (847) 420-9540, Rachael Jarnagin, (224) 360-2146; Abbott Financial: Mike Comilla, (224) 668-1872

Additional assets available online:

